Answers are grounded in this paper and cite their sources.
A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of ( R )- tert -butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of its iminoindan precursor.
No takes yet. Share an insight, caveat, or question.
LUKIN et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: